Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $33,618.60 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 58,980 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $0.57, for a total transaction of $33,618.60. Following the completion of the sale, the director directly owned 2,309,869 shares in the company, valued at $1,316,625.33. This trade represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Luke Evnin also recently made the following trade(s):

• On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total transaction of $15,053.58.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total value of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.62, for a total transaction of $15,476.44.
• On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total transaction of $21,256.67.
• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total transaction of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $22,448.16.

Werewolf Therapeutics Price Performance

Shares of Werewolf Therapeutics stock traded down $0.03 during trading hours on Monday, reaching $0.57. The stock had a trading volume of 1,049,698 shares, compared to its average volume of 414,643. The stock’s 50 day moving average is $0.89 and its 200 day moving average is $1.25. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a twelve month low of $0.56 and a twelve month high of $2.38. The firm has a market capitalization of $27.89 million, a PE ratio of -0.35 and a beta of 0.77.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.03. Equities analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quadrature Capital Ltd purchased a new stake in shares of Werewolf Therapeutics in the 2nd quarter valued at approximately $28,000. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics in the second quarter valued at approximately $48,000. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics in the first quarter worth approximately $79,000. Y Intercept Hong Kong Ltd acquired a new stake in Werewolf Therapeutics during the second quarter worth $92,000. Finally, Bridgeway Capital Management LLC raised its position in Werewolf Therapeutics by 157.7% in the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after purchasing an additional 62,414 shares during the period. Institutional investors and hedge funds own 64.84% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Citigroup downgraded Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Citizens Jmp lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Zacks Research lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Finally, HC Wainwright cut their target price on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Werewolf Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.